Blocking small knee blood vessels for knee osteoarthritis pain that persists despite usual care
Tests Nexsphere-F embolization in people with knee osteoarthritis whose pain stays uncontrolled.
Key facts
- Who runs it
- Next Biomedical Co., Ltd.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 23 Oct 2023
- Planned end
- Dec 2025
- Type of study
- Interventional
- Treatments tested
- Transcatheter Arterial Micro-Embolization
- Record updated
- 2 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 50 years with knee osteoarthritis (wear-and-tear arthritis). Their knee pain must still be poorly controlled after usual treatments. They will have Nexsphere-F embolization, which blocks small blood vessels.
- Age
- Over 50 years (minimum age 50 Years)
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis of Kellgren-Lawrence grade 2 to 3 on X-ray within 12 months. Pain score (VAS) above 50mm.
- Earlier treatment
- Must have had Glucosamine chondroitin sulfate, physical therapy and rehabilitation exercises, and hyaluronic acid knee injections for more than 12 weeks. Must keep current medicines and start no new knee pain treatments during the trial.
Main reasons for not taking part
- Local infection, rheumatism or infectious arthritis, or life expectancy less than six months
- Leg symptoms caused by narrowed or diseased arteries, such as pain when walking
- Past knee replacement surgery
- Severe iodine allergy, INR 2.5 or platelets less than 30,000, or eGFR less than 45 within the last 60 days
- Pregnant women, or people who cannot have MRI scans
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Those who fall under Kellgren-Lawrence grade 2 to 3 according to the criteria in accordance with ACR guidelines and X-ray findings used within 12 months
- VAS score exceeding 50mm
- An adult male and female over 50 years of age
- Preservative therapy Glucosamine chondroitin sulfate/physiological therapy and rehabilitation exercises, and joint injections of hyaluronic acid for more than 12 weeks
- A person who agrees to maintain existing medication treatments during the clinical trial period but does not receive additional medication or new conservative treatments for knee osteoarthritis pain management
Who cannot take part
- A person who has not had knee microfracture surgery for more than 10 years
- A locally infected patient
- A person with symptoms of lower extremities that are considered secondary to atherosclerosis or arterial vascular disease (ex: claudication ischemic rest pain)
- Anaphylaxis-causing iodine allergy
- INR 2.5 or less than 30,000 platelets
- Patients with renal dysfunction or impaired renal function who have been diagnosed with less than 45 GFR (eGFR) within the last 60 days
- A person whose life expectancy is less than six months
- A person diagnosed with rheumatism or infectious arthritis
- A person who has undergone knee arthroplasty
- Those who have a taboo on MR videos
- Pregnant women
- Other cases where it is deemed inappropriate to participate in this clinical trial at the discretion of the researcher
Where in South Korea
- Severance hospitalSeoul, South KoreaContact: Hyuckmin KwonTaking people
About the trial
What the trial wants to find out
Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the therapeutic effect and safety of Nexsphere-F embolization for patients who need additional treatment because pain is not controlled even if conventional treatments are taken.
The group in the trial
- Transcatheter Arterial Micro-EmbolizationTreatment being tested
If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single Arm, Single Center, Open Label , Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro Embolization (TAME) Using Nexsphere F in Patients With Knee Degenerative Osteoarthritis
- Plain-language title
- Blocking small knee blood vessels for knee osteoarthritis pain that persists despite usual careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 April 2025